News

12. July 2022

LegoChem Biosciences and Glycotope Announce Research Collaboration and License Agreement for an Antibody for use as Antibody Drug Conjugate

Read Article

8. April 2022

Glycotope Presents New Data on Antibodies and Fusion-Proteins against GlycoTargets at the 2022 American Association for Cancer Research (AACR) Meeting

Read Article

24. March 2022

Glycotope Announces New Strategy to Maximize Potential of Uniquely-Tumor Specific Antibody Platform

Read Article

1. February 2022

Glycotope to spin-out its Service Business to the newly formed FyoniBio GmbH

Read Article

15. November 2021

Glycotope Presents New Data on Carbohydrate-Dependent Antibodies and Fusion-Proteins at the 2021 Society for Immunotherapy of Cancer (SITC) Meeting

Read Article

16. June 2021

Glycotope Poster Presentation at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

Read Article

30. April 2021

Glycotope Announces Poster Presentations at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

Read Article

21. September 2020

DCprime and Glycotope Sign Licensing Agreement to Advance Program Combining Cancer Vaccination and Therapeutic Antibody Platforms

Read Article

30. July 2018

Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate

Read Article

18. July 2018

DCprime and Glycotope announce licensing agreement and collaboration

Read Article